I left town on July the 8th and came back last night. Today, I get the same Google results that I got the day I left. I guess they’re just not going to publish their results and hope the short news cycle just lets the story die. I think I must just be terribly naive. […]
Personalized Biological Testing In Psychiatry: Inevitable Reality or Impossible Dream? Psychiatric Times By Allen Frances, MD July 18, 2012 At next year’s meeting of The International College of Neuropsychopharmacology [Collegium Internationale Neuro-Psychopharmacologicum, or CINP], the smartest people in psychiatric genetics will present their suggestions and report on progress in applying the techniques of personalized medicine […]
Pharma’s Top 11 Marketing Settlements FiercePharma By Tracy Staton and Eric Palmer June 26, 2012 The Justice Department is growing more and more impatient. For more than a decade, its lawyers and investigators have been slapping drugmakers around for their marketing misdoings. They’ve insisted on bigger and bigger penalties, especially during the last several years, […]
There is probably no single icon for the corruption of the modern psychiatric literature so paradigmatic as Glaxo-SmithKline’s Study 329 and its publication in 2001 by then Brown University’s Chairman of Psychiatry, Dr. Martin Keller: Efficacy of Paroxetine in the Treatment of Adolescent Major Depression: A Randomized, Controlled Trial by MARTIN B. KELLER, M.D., NEAL […]
“The real voyage of discovery consists not in seeking new landscapes, but in having new eyes.” Marcel Proust – À la recherche du temps perdu A CONTROLLED TRIAL OF IMIPRAMINE IN TREATMENT OF DEPRESSIVE STATES BY J. R. B. BALL AND L. G. KILOH British Medical Journal. 1959 2:5199:1052-1055. [full text on-line] All the cases […]
GSK Study 329 has become the symbol of the corruption of the psychiatric literature [retract study 329…]. As we all know, The published article concluded, "Paroxetine is generally well tolerated and effective for major depression in adolescents." Among the documents released with the $3B fining of GSK [Biggest Deal Ever: Glaxo Pays $3B For Bad […]
What do you call it when two mutually exclusive things are both happening? It’s not a double bind, or a dilemma – maybe something more like a a paradox? a conundrum? an enigma? On one side of the equation, the press is filled with huge financial penalties levied on the manufacturers of psychiatric drugs for […]
“Just saw Mickey’s ‘Ode to … ‘ — delightful video. Here’s one that’s been around for a while, but equally delightful: a little boy conducting a Beethoven symphony. Amazingly, he obviously knows the music and anticipates what’s coming next. Watch to the end . . . so cute. What to do when your nose itches? […]
Biggest Deal Ever: Glaxo Pays $3B For Bad Behavior Pharmalot By Ed Silverman July 2nd, 2012 In the largest such deal to date, GlaxoSmithKline agreed to plead guilty and pay $3 billion to resolve criminal and civil charges in connection with off-label promotion of several drugs, failing to report safety data and reporting false prices. […]